Renaissance Technologies's ALDX Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 350,000 shares of Aldeyra Therapeutics, Inc. (ALDX) worth $1.81 M, representing 0.00% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in ALDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 517,200 shares. Largest reduction occurred in Q2 2020, reducing 516,782 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Aldeyra Therapeutics (ALDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aldeyra Therapeutics (ALDX) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +152,700 | Add 77.39% | 350,000 | $5.18 |
| Q3 2025 | +84,500 | Add 74.91% | 197,300 | $5.22 |
| Q2 2025 | -3,800 | Reduce 3.26% | 112,800 | $3.83 |
| Q1 2025 | -50,500 | Reduce 30.22% | 116,600 | $5.75 |
| Q4 2024 | +59,700 | Add 55.59% | 167,100 | $4.99 |
| Q3 2024 | -395,900 | Reduce 78.66% | 107,400 | $5.39 |
| Q2 2024 | -224,390 | Reduce 30.84% | 503,300 | $3.31 |
| Q1 2024 | +427,690 | Add 142.56% | 727,690 | $3.27 |
| Q4 2023 | +78,200 | Add 35.26% | 300,000 | $3.51 |
| Q3 2023 | -83,556 | Reduce 27.36% | 221,800 | $6.68 |
| Q2 2023 | +57,956 | Add 23.43% | 305,356 | $0.01 |
| Q1 2023 | +33,900 | Add 15.88% | 247,400 | $0.01 |
| Q4 2022 | -164,800 | Reduce 43.56% | 213,500 | $0.01 |
| Q3 2022 | -135,800 | Reduce 26.42% | 378,300 | $5.34 |
| Q2 2022 | +514,100 | New Buy | 514,100 | $3.99 |
| Q1 2021 | -53,800 | Sold Out | 0 | $0.00 |
| Q4 2020 | +53,800 | New Buy | 53,800 | $6.86 |
| Q3 2020 | -79,618 | Sold Out | 0 | $0.00 |
| Q2 2020 | -516,782 | Reduce 86.65% | 79,618 | $4.17 |
| Q1 2020 | +517,200 | Add 653.03% | 596,400 | $2.47 |
| Q4 2019 | +79,200 | New Buy | 79,200 | $5.81 |
| Q3 2019 | -90,200 | Sold Out | 0 | $0.00 |
| Q2 2019 | +90,200 | New Buy | 90,200 | $6.00 |
| Q1 2019 | -12,000 | Sold Out | 0 | $0.00 |
| Q4 2018 | +700 | Add 6.19% | 12,000 | $8.33 |
| Q3 2018 | -11,800 | Reduce 51.08% | 11,300 | $13.81 |
| Q2 2018 | -7,500 | Reduce 24.51% | 23,100 | $7.97 |
| Q1 2018 | -31,500 | Reduce 50.72% | 30,600 | $7.52 |
| Q4 2017 | -23,100 | Reduce 27.11% | 62,100 | $6.80 |
| Q3 2017 | +29,900 | Add 54.07% | 85,200 | $7.19 |
| Q2 2017 | +29,000 | Add 110.27% | 55,300 | $4.65 |
| Q1 2017 | +26,300 | New Buy | 26,300 | $5.02 |
Renaissance Technologies's Aldeyra Therapeutics Investment FAQs
Renaissance Technologies first purchased Aldeyra Therapeutics, Inc. (ALDX) in Q1 2017, acquiring 26,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Aldeyra Therapeutics, Inc. (ALDX) for 32 quarters since Q1 2017.
Renaissance Technologies's largest addition to Aldeyra Therapeutics, Inc. (ALDX) was in Q1 2020, adding 596,400 shares worth $1.47 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 350,000 shares of Aldeyra Therapeutics, Inc. (ALDX), valued at approximately $1.81 M.
As of the Q4 2025 filing, Aldeyra Therapeutics, Inc. (ALDX) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Aldeyra Therapeutics, Inc. (ALDX) was 727,690 shares, as reported at the end of Q1 2024.